BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference

Reuters10-30

Oct 30 (Reuters) - Lexeo Therapeutics Inc :

* LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE

* LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA

* LEXEO THERAPEUTICS - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479727672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479727672","market":"us","top_or_hot":-1,"title":"BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference","media":"Reuters","content":"<html><body><p>Oct 30 (Reuters) - <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> Inc   :</p><p>   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE</p><p>   * LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA</p><p>   * LEXEO THERAPEUTICS  - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lexeo Therapeutics Announces Positive Interim Data For Lx1001, First-Ever Gene Therapy To Impact The Underlying Genetic Cause Of Apoe4-Associated Alzheimer’S Disease, At The Clinical Trials On Alzheimer’S Disease (Ctad) Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 18:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 30 (Reuters) - Lexeo Therapeutics Inc   :   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LXEO","symbol_name":"Lexeo Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2479727672","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479727672","pubTimestamp":1730285595,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 30  - Lexeo Therapeutics Inc   :   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE  CONFERENCE   * LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA   * LEXEO THERAPEUTICS  - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LXEO":"Lexeo Therapeutics","GENE":"基因技术ADR","BK4121":"生命科学工具和服务","BK4139":"生物科技"},"translate_title":"简介-Lexeo Therapeutics在阿尔茨海默病临床试验(Ctad)会议上宣布了Lx1001的积极中期数据，这是有史以来第一种影响Apoe4相关阿尔茨海默病潜在遗传原因的基因疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GENE":1,"LXEO":1},"content_text":"Oct 30 (Reuters) - Lexeo Therapeutics Inc   :   * LEXEO THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FOR LX1001, FIRST-EVER GENE THERAPY TO IMPACT THE UNDERLYING GENETIC CAUSE OF APOE4-ASSOCIATED ALZHEIMER’S DISEASE, AT THE CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE   * LEXEO THERAPEUTICS INC - LX1001 WELL TOLERATED WITH NO REPORTS OF ARIA   * LEXEO THERAPEUTICS  - SEES FURTHER LX1001 DEVELOPMENT PLANS IN 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479727672"}